Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo diterpene lactone meglumine injection for atherosclerotic cerebral small vessel disease
ChiCTR2100050965Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Ginkgo diterpene lactone meglumine in Cerebral Small Vessel Disease (CSVD), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: blood oxygen level dependent fMRI, dynamic enhanced MRI and 5 more. Started Sep 2021; status: recruiting.
02
Drugs
Ginkgo diterpene lactone meglumine
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on ChiCTR2100050965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050965.